Eli Lilly agreed to acquire Engage Biologics in a deal worth up to $202 million, adding preclinical non-viral DNA delivery capabilities to its genetic medicines pipeline. Engage’s platform, called Tethosome, is designed to deliver DNA using lipid nanoparticles rather than viral vectors, leveraging engineered DNA payloads and an mRNA-encoded transport component intended to drive expression while improving tolerability and re-dosing flexibility. Lilly positioned the acquisition as accelerating the development of genetic therapies, citing long-standing barriers to uptake driven by AAV vector safety considerations, manufacturing constraints, and high costs. Engage had raised seed capital from investors including Y Combinator and the Cystic Fibrosis Foundation. The acquisition continues Lilly’s rapid deal cadence in genetic medicine, following earlier purchases that expanded its pipeline for genetic therapies and in vivo cell approaches. For Engage, being folded into a larger development engine could reduce translational friction and strengthen the path toward IND-enabling studies. The deal also underscores how non-viral delivery has become a strategic priority for Big Pharma as it looks for alternatives to AAV for broader patient reach.